GlaxoSmithKline to Acquire Genelabs Technologies For $57M

|
 |  Includes: GNLB, GSK
by: Eben Tessari

I’m a huge fan of early stage deals with lots of upside and a cost under $75M.

GlaxoSmithKline, looking to shore up their hepatitis C pipeline, announced that they have entered into an agreement with Genelabs Technologies for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash.